OC-0625 Immuno-radiotherapy in solid tumors: preliminary results of the randomized phase 2 CHEERS trial

Spaas, Mathieu; Sundahl, Nora; Rottey, Sylvie; Krüse, Vibeke; Maeseneer, Daan De; Duprez, Frédéric; Dirix, Piet; Surmont, Veerle; Lievens, Yolande; Begin, Robbe Van den; Gestel, D. Van; Renard, Vincent; Reynders, Dries; Goetghebeur, Els; Ost, P.

doi:10.1016/s0167-8140(21)06981-4

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Objective response rate (ORR) did not differ significantly between both arms (22% vs. 27%; P=0.5), despite a LCR of 77% in irradiated patients. Treatment related toxicities were similar (47).…”

Section: Abscopal Effectmentioning

confidence: 79%

Oligoprogression in non-small cell lung cancer: a narrative review

Nguyen¹,

Sakthivel²,

Milano³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

Background and Objective: Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancers and is the most common non-cutaneous cancer world-wide. In NSCLC, oligometastatic and oligoprogressive disease (OPD) have been recognized as separate entities within the realm of metastatic disease and are emerging concepts in the context of targeted systemic therapies. Our objectives are to discuss the current literature regarding the evolving definitions of OPD in the context of oligometastatic disease (OMD) for NSCLC. Further, to discuss current and future clinical trials that have shaped our local approach with stereotactic body radiation therapy (SBRT)/stereotactic ablative radiotherapy (SABR).Methods: Literature on OPD in NSCLC and local ablative therapy (LAT) including SBRT/SABR and stereotactic radiosurgery (SRS) was reviewed.Key Content and Findings: Oligoprogression is defined as limited (usually 3-5) metastatic areas progressing while on/off systemic therapy in the background of oligometastatic or polymetastatic disease.Prognosis in OPD with treatment (such as LAT and systemic therapy) may be more favorable. Outcomes for patients progressing on tyrosine kinase inhibitors (TKIs) with molecular mutations [such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK)] who receive LAT are promising.Conclusions: Patients presenting with NSCLC metastasis with progression at a limited number of sites on/off a given line of systemic therapy may have favorable outcomes with aggressive LAT, which includes SBRT/SABR/SRS. Further studies need to be completed to further optimize treatment recommendations.

show abstract

Section: Abscopal Effectmentioning

confidence: 79%

Oligoprogression in non-small cell lung cancer: a narrative review

Nguyen¹,

Sakthivel²,

Milano³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…The CHEERS trial evaluated the addition of SBRT to immunotherapy in metastatic solid tumors and included a small subgroup (n 5 20) of HNSCC patients. 50 There were no restrictions on number of metastases. Investigators selected the anti-PD-(L)1 immunotherapy, with the timing and SBRT schema like McBride et al 32 (24 Gy in three fractions, treating up to a maximum of three lesions started after completion of cycle 1 of immunotherapy).…”

Section: Clinical Questionmentioning

confidence: 99%

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Yilmaz

Ismaila

Bauman

et al. 2023

JCO

View full text Add to dashboard Cite

PURPOSE To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers. METHODS ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 28 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS When possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence. Additional information is available at www.asco.org/head-neck-cancer-guidelines .

show abstract

“…A pooled analysis of the PEMBRO-RT and MDACC trials assessed metastatic NSCLC patients receiving pembrolizumab with or without radiotherapy found that patients undergoing radiation had a higher abscopal response rate (41.7% vs. 19.7%) [ 41 ]. However, other phase II clinical trials that evaluated the combination of SABR and immunotherapy have failed to demonstrate the abscopal effect in a variety of histologies [ 42 ] including renal cell carcinoma [ 43 ], head and neck [ 44 ], NSCLC [ 45 ], cervical/endometrial [ 46 ] and colorectal cancer [ 47 ]. This includes the ongoing CHEERS trial, a multicenter phase II trial randomizing locally advanced or metastatic patients to receive SABR and anti-PD-(L)1 immunotherapy or immunotherapy alone.…”

Section: Lesson #9: Don’t Count On the Abscopal Effectmentioning

confidence: 99%

“…This includes the ongoing CHEERS trial, a multicenter phase II trial randomizing locally advanced or metastatic patients to receive SABR and anti-PD-(L)1 immunotherapy or immunotherapy alone. Preliminary results presented at ESTRO 2021 found that there was no effect on PFS, with a median PFS of 4.4 months in the experimental arm and median PFS of 2.8 months in the standard arm [ 42 ]. Another example is the phase II trial conducted by McBride et al [ 44 ] randomizing metastatic head and neck squamous cell carcinoma to nivolumab plus SABR versus nivolumab alone.…”

Section: Lesson #9: Don’t Count On the Abscopal Effectmentioning

confidence: 99%

Top Ten Lessons Learned from Trials in Oligometastatic Cancers

Tan

Palma

2023

Cancer Res Treat

View full text Add to dashboard Cite

Recent evidence supports the role of aggressive local treatment in the oligometastatic setting.In this review, we discuss the top 10 lessons we have learned from trials in oligometastatic cancers. Major lessons learned pertain to definitions of oligometastatic disease, outcomes, toxicity, costs, and the combination of ablative therapies with systemic therapy, including immunotherapy. Barriers to accrual for trials and upcoming phase III trials are also reviewed.These lessons may help to inform clinical practice and may be the basis for future research in the oligometastatic space.

show abstract

OC-0625 Immuno-radiotherapy in solid tumors: preliminary results of the randomized phase 2 CHEERS trial

Cited by 10 publications

References 0 publications

Oligoprogression in non-small cell lung cancer: a narrative review

Oligoprogression in non-small cell lung cancer: a narrative review

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Top Ten Lessons Learned from Trials in Oligometastatic Cancers

Contact Info

Product

Resources

About